This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Axcan Pharma gets rights to Merz's cirrhosis therapeutic
19 Aug 2003
Axcan Pharma has received an exclusive license from Merz Pharmaceuticals to develop injectable and oral granule formulations that contain L-ornithine and L-aspartate. The drugs are used to treat hepatic encephalopathy (HE) that may accompany early- to late-stage liver cirrhosis.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?